Nanobiotix S.A.

BATS-CHIXE:NANOP Stock Report

Market Cap: €230.0m

Nanobiotix Management

Management criteria checks 2/4

Nanobiotix's CEO is Laurent Levy, appointed in Mar 2003, has a tenure of 20.58 years. total yearly compensation is €1.39M, comprised of 27.3% salary and 72.7% bonuses, including company stock and options. directly owns 3.15% of the company’s shares, worth €7.24M. The average tenure of the management team and the board of directors is 4.3 years and 0.9 years respectively.

Key information

Laurent Levy

Chief executive officer

€1.4m

Total compensation

CEO salary percentage27.3%
CEO tenure20.6yrs
CEO ownership3.1%
Management average tenure4.3yrs
Board average tenureless than a year

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Laurent Levy's remuneration changed compared to Nanobiotix's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-€59m

Mar 31 2023n/an/a

-€58m

Dec 31 2022€1m€380k

-€57m

Sep 30 2022n/an/a

-€50m

Jun 30 2022n/an/a

-€43m

Mar 31 2022n/an/a

-€45m

Dec 31 2021€4m€380k

-€47m

Sep 30 2021n/an/a

-€45m

Jun 30 2021n/an/a

-€43m

Mar 31 2021n/an/a

-€39m

Dec 31 2020€818k€330k

-€34m

Sep 30 2020n/an/a

-€41m

Jun 30 2020n/an/a

-€48m

Mar 31 2020n/an/a

-€49m

Dec 31 2019€2m€330k

-€51m

Sep 30 2019n/an/a

-€46m

Jun 30 2019n/an/a

-€42m

Mar 31 2019n/an/a

-€36m

Dec 31 2018€1m€300k

-€30m

Sep 30 2018n/an/a

-€28m

Jun 30 2018n/an/a

-€27m

Mar 31 2018n/an/a

-€26m

Dec 31 2017€861k€253k

-€26m

Sep 30 2017n/an/a

-€25m

Jun 30 2017n/an/a

-€24m

Mar 31 2017n/an/a

-€23m

Dec 31 2016€730k€206k

-€22m

Compensation vs Market: Laurent's total compensation ($USD1.48M) is above average for companies of similar size in the UK market ($USD745.84K).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.

CEO

Laurent Levy (50 yo)

20.6yrs

Tenure

€1,393,145

Compensation

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Leadership Team

NamePositionTenureCompensationOwnership
Laurent Levy
Co-Founder20.6yrs€1.39m3.15%
€ 7.2m
Bart Van Rhijn
CFO & Member of Executive Board2.3yrs€866.64k0%
€ 0
Anne-Juliette Hermant
Chief People Officer & Member of Executive Board4.3yrs€486.62k0.39%
€ 890.4k
Earl Bergey
Co-Founder20.8yrsno datano data
Alain Dostie
Chief Operating Officer6.7yrsno datano data
Kathryn McNeil
Senior Vice President of Investor Relationsno datano datano data
Brandon Owens
VP of Strategic Marketing & Corporate Communicationno datano datano data
Patrick Tricoli
Global Head of Business Development4.3yrsno datano data
Margaret Galluzzi
VP & Global Head of Clinical Operations4.8yrsno datano data
Ventzislav Vassilev
VP & Global Head of Safety Vigilance3.4yrsno datano data
Leonard Farber
Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board1.7yrsno datano data
Louis Kayitalire
Chief Medical Officerless than a yearno datano data

4.3yrs

Average Tenure

50yo

Average Age

Experienced Management: NANOP's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Leonard Farber
Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Boardno datano datano data
Enno Spillner
Independent Member of Supervisory Board9.3yrs€50.00kno data
Christophe Douat
Supervisory Board Observer6.3yrs€35.00kno data
Gary Phillips
Independent Chairman of Supervisory board2.4yrs€63.00kno data
Silvia Formenti
Member of Scientific Advisory Boardless than a yearno datano data
Alain Herrera
Independent Member of Supervisory Board10.3yrs€35.00kno data
Anne-Marie Graffin
Independent Vice Chairman of the Supervisory Board9.8yrs€42.00kno data
Hisham Mehanna
Member of Scientific Advisory Boardless than a yearno datano data
Stephane Champiat
Member of Scientific Advisory Boardless than a yearno datano data
Jean Bourhis
Member of Scientific Advisory Boardless than a yearno datano data
Thierry Baere
Member of Scientific Advisory Boardless than a yearno datano data
Christophe Tourneau
Member of Scientific Advisory Boardless than a yearno datano data

0.9yrs

Average Tenure

57yo

Average Age

Experienced Board: NANOP's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/08 08:27
End of Day Share Price 2023/07/11 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanobiotix S.A. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mickael Chane-DuBryan Garnier & Co
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI